Knotus Co Ltd
KOSDAQ:278650
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 995
4 510
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Knotus Co Ltd
Cash & Cash Equivalents
Knotus Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Cash & Cash Equivalents
â‚©68.8B
|
CAGR 3-Years
105%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Cash & Cash Equivalents
â‚©973.5B
|
CAGR 3-Years
129%
|
CAGR 5-Years
147%
|
CAGR 10-Years
N/A
|
||
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cash & Cash Equivalents
â‚©50.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Cash & Cash Equivalents
â‚©5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cash & Cash Equivalents
â‚©15.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
61%
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Cash & Cash Equivalents
â‚©589.8m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
Knotus Co Ltd
Glance View
KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.
See Also
What is Knotus Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
68.8B
KRW
Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Cash & Cash Equivalents amounts to 68.8B KRW.
What is Knotus Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
83%
Over the last year, the Cash & Cash Equivalents growth was 363%. The average annual Cash & Cash Equivalents growth rates for Knotus Co Ltd have been 105% over the past three years , 83% over the past five years .